Dyslipidemia Drug Indications

DYSLIPIDEMIA DRUG INDICATIONS
Generic Brand Form Indications
Slow
coronary
athero-
sclerosis		 Lower
total-C		 Lower
LDL-C		 Increase
HDL-C		 Lower
apo B		 Lower
TG		 Sitosterol/
campe-
sterol		 Reduce
risk of
CVD4
ADENOSINE TRIPHOSPHATE-CITRATE LYASE (ACL) INHIBITOR + CHOLESTEROL ABSORPTION INHIBITOR
bempedoic acid + ezetimibe Nexlizet tabs ✓ ✓ ✓    
BILE ACID SEQUESTRANTS
cholestyr–
amine resin		 — pwd ✓   ✓
colesevelam Welchol tabs,
oral susp		 ✓
colestipol Colestid tabs,
granules		 ✓ ✓
CHOLESTEROL ABSORPTION INHIBITOR
ezetimibe Zetia tabs ✓ ✓ ✓ ✓2
FIBRATES
fenofibrate Antara caps ✓ ✓ ✓ ✓ ✓
Fenoglide tabs ✓ ✓ ✓ ✓ ✓
Lipofen caps ✓ ✓ ✓ ✓ ✓
Tricor tabs ✓ ✓ ✓ ✓ ✓
Triglide tabs ✓ ✓ ✓ ✓ ✓
fenofibric acid Fibricor tabs ✓ ✓ ✓ ✓ ✓
Trilipix del-rel caps ✓ ✓ ✓ ✓ ✓
LIPID-REGULATING AGENT
gemfibrozil Lopid scored tabs ✓1 ✓ ✓
icosapent ethyl Vascepa caps ✓ ✓
omega-3-acid
ethyl esters		 Lovaza caps ✓
MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITOR
lomitapide mesylate Juxtapid caps ✓ ✓3 ✓
NICOTINIC ACID DERIVATIVES
niacin Niaspan ext-rel tabs ✓ ✓ ✓ ✓ ✓ ✓ ✓
PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) INHIBITOR
alirocumab Praluent SC inj ✓ ✓
evolocumab Repatha SC inj ✓ ✓
Repatha Pushtronex SC inj ✓ ✓
STATINS (HMG-CoA REDUCTASE INHIBITORS)
atorvastatin Lipitor tabs ✓ ✓ ✓ ✓ ✓ ✓
fluvastatin Lescol caps ✓ ✓ ✓ ✓ ✓ ✓ ✓
Lescol XL ext-rel tabs ✓ ✓ ✓ ✓ ✓ ✓ ✓
lovastatin — tabs ✓ ✓ ✓ ✓ ✓ ✓
Altoprev ext-rel tabs ✓ ✓ ✓ ✓ ✓ ✓ ✓
pitavastatin Livalo tabs ✓ ✓ ✓ ✓ ✓
Zypitamag tabs ✓ ✓ ✓ ✓ ✓
pravastatin Pravachol tabs ✓ ✓ ✓ ✓ ✓ ✓ ✓
rosuvastatin Crestor tabs ✓ ✓ ✓3 ✓ ✓ ✓ ✓
Ezallor Sprinkle caps ✓ ✓ ✓ ✓ ✓  
simvastatin Zocor tabs ✓ ✓ ✓ ✓ ✓ ✓
STATIN + CALCIUM CHANNEL BLOCKER
atorvastatin +
amlodipine		 Caduet tabs ✓ ✓ ✓ ✓ ✓ ✓
STATIN + CHOLESTEROL ABSORPTION INHIBITOR
simvastatin +
ezetimibe		 Vytorin tabs ✓ ✓ ✓ ✓ ✓
Classification of Hyperlipoproteinemias
Fredrickson Type    Elevated Lipoproteins     Lipid Elevations (Major)      Lipid Elevations (Minor)
I (rare) chylomicrons triglycerides total-C elevated or no change
IIa LDL total-C —
IIb LDL, VLDL total-C triglycerides
III (rare) IDL total-C/triglycerides —
IV VLDL triglycerides total-C elevated or no change
V chylomicrons, VLDL triglycerides total-C elevated or no change
NOTES

Key:  apo B = apolipoprotein B; 
TG = triglycerides; 
total-C = total cholesterol; 
LDL-C = low-density lipoproteins; 
CVD = cardiovascular disease; 
IDL = intermediate-density lipoproteins; 
VLDL = very low density lipoproteins; 
HDL-C = high-density lipoproteins

1 Reduction in risk of coronary artery disease when first line
agent is inadequate

2 To reduce elevated sitosterol and campesterol in homozygous
familial sitosterolemia

3 Also to reduce elevated non-HDL-C (total-C minus HDL-C)

4 To reduce risk of: MI, stroke, or coronary
revascularization procedures, and morbidity/mortality.

FDA-approved indications marked with a ✓. Not an inclusive list of
medications and/or official indications. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.
Listed indications may be adjuncts to other therapies, lifestyle changes and/or concomitant drugs.

(Rev. 10/2020)

This article originally appeared on MPR

Topics:

Cardiology Cardiovascular Disease Dyslipidemia Hyperlipoproteinemias